NCT03377179View on ClinicalTrials.gov

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 7, 2018

Primary Completion Date

June 21, 2022

Study Completion Date

June 21, 2022

Conditions

CholangiocarcinomaCholangiocarcinoma Non-resectableCholangiocarcinoma, PerihilarCholangiocarcinoma, ExtrahepaticCholangiocarcinoma, Intrahepatic

Interventions

DRUG

ABC294640

Two 250 mg capsules of ABC294640 will be taken twice daily

DRUG

Hydroxychloroquine Sulfate 200 MG

HCQ tablets will be taken at a dose that will be determined

Trial Locations (5)

30322

Emory University, Atlanta

55905

Mayo Clinic Cancer Center, Rochester

77030

MD Anderson Cancer Center, Houston

84103

Huntsman Cancer Institute, University of Utah, Salt Lake City

85054

Mayo Clinic Cancer Center, Phoenix

All Listed Sponsors

lead

RedHill Biopharma Limited

INDUSTRY

NCT03377179 - A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma | Biotech Hunter | Biotech Hunter